1. Buhaş MC, Gavrilaş LI, Candrea R, et al. Gut microbiota in psoriasis. Nutrients 2022;14:2970.

2. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899–1912.

3. Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983–994.

4. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007;33:45–56.

5. Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779–798.

6. Bojović K, Ignjatović ĐI, Soković Bajić S, et al. Gut microbiota dysbiosis associated with altered production of short chain fatty acids in children with neurodevelopmental disorders. Front Cell Infect Microbiol 2020;10:223.

7. Eslick S, Williams EJ, Berthon BS, et al. Weight loss and short-chain fatty acids reduce systemic inflammation in monocytes and adipose tissue macrophages from obese subjects. Nutrients 2022;14:765.

8. Rorato R, Borges BC, Uchoa ET, Antunes-Rodrigues J, Elias CF, Elias LLK. LPS-induced low-grade inflammation increases hypothalamic JNK expression and causes central insulin resistance irrespective of body weight changes. Int J Mol Sci 2017;18:1431.

9. Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. Cell 2021;184:4137–4153e14.

10. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128–139.

11. Visser MJE, Kell DB, Pretorius E. Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol 2019;9:7.

12. Lin HC, Chen YY, Lin HL, Uang YS, Ho Y, Wang LH. Association between acid-suppressive drug use and atopic dermatitis in patients with upper gastrointestinal diseases: a population-based retrospective cohort study. J Clin Pharm Ther 2021;46:786–793.

13. Zhu J, Sun C, Li M, Hu G, Zhao XM, Chen WH. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial. Gut 2024;73:1087–1097.

14. Hojo M, Asahara T, Nagahara A, et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci 2018;63:2940–2949.

15. Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal microbiome - what we need to know in clinical practice. GE Port J Gastroenterol 2020;27:336–351.

17. Kim JH, Min JH, Jo YW, Kwon JW, Her Y. Association between acid-suppressive drugs and risk of rosacea: retrospective study using the Korean National Health Insurance Service-national sample cohort. J Korean Med Sci 2023;38:e402.

18. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017;76:377–390.

19. Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013;28:235–242.

20. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016;65:749–756.

21. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047–2056quiz 2057.

22. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017;153:35–48.

23. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60:940–947.

24. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007;51:2883–2887.

25. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992;33:617–621.

26. Kanno T, Matsuki T, Oka M, et al. Gastric acid reduction leads to an alteration in lower intestinal microflora. Biochem Biophys Res Commun 2009;381:666–670.

27. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54–59.

28. Valdimarsson H, Baker BS, Jónsdóttir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995;16:145–149.

29. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl) 2017;7:87–94.

30. Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease. Digestion 2017;95:188–193.

31. Hidalgo-Cantabrana C, Gómez J, Delgado S, et al. Gut microbiota dysbiosis in a cohort of patients with psoriasis. Br J Dermatol 2019;181:1287–1295.

32. Kierasińska M, Donskow-Łysoniewska K. Both the microbiome and the macrobiome can influence immune responsiveness in psoriasis. Cent Eur J Immunol 2021;46:502–508.

33. Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol 2019;46:595–603.

34. Le ST, Toussi A, Maverakis N, et al. The cutaneous and intestinal microbiome in psoriatic disease. Clin Immunol 2020;218:108537.

35. Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D. Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur J Immunol 2004;34:2520–2528.

36. Guéniche A, Benyacoub J, Buetler TM, Smola H, Blum S. Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure. Eur J Dermatol 2006;16:511–517.

37. O’Neill CA, Monteleone G, McLaughlin JT, Paus R. The gut-skin axis in health and disease: a paradigm with therapeutic implications. Bioessays 2016;38:1167–1176.

38. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008;6:759–764.

39. Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review. Pathogens 2020;9:463.

40. Szántó M, Dózsa A, Antal D, Szabó K, Kemény L, Bai P. Targeting the gut-skin axis-Probiotics as new tools for skin disorder management? Exp Dermatol 2019;28:1210–1218.

41. Arck P, Handjiski B, Hagen E, et al. Is there a ‘gut-brain-skin axis’? Exp Dermatol 2010;19:401–405.